Search clinical trials for: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)

Total 215 results

B. Braun Melsungen AG

Completed

Non-Interventional (Observational) Post-Authorization Safety Study of HES 130/0.42 in Paediatric Patients

Surgery

Germany, Austria, Czech Republic, Italy, Netherlands
B. Braun Melsungen AG

Completed

Safety Profile of Hydroxyethyl Starch

Plasma Volume Replacement

Malaysia, China
Paraskevi Matsota

Completed

The Effect of Intravenous Prehydration on the Hemodynamic Status of Healthy Parturients Undergoing Spinal Anesthesia for Cesarean Delivery

Hypotension

Greece
B. Braun Melsungen AG

Completed

Comparison of HES 130 in Balanced and in Unbalanced Solution

Decreased and Nonspecific Blood Pressure Disorders and Shock

China
Klinikum Ludwigshafen

Completed

A Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients

Cardiac Surgery | Elderly

Germany
Haukeland University Hospital

Completed

The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols

Coronary Heart Disease

Norway
Kasr El Aini Hospital

Unknown

Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures

Urologic Surgical Procedures

Egypt
Sangart

Completed

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Vascular Disease | Critical Lower Limb Ischemia

Sweden
Sifa University

Unknown

Colloid Preload Versus Colloid Coload During Cesarean Deliveries

Hypotension | Anesthesia; Adverse Effect, Spinal and Epidural

Turkey
Cliniques universitaires Saint-Luc- Université...

Completed

Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery

Kidney Function Tests
Sangart

Completed

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Ischemia | Hypotension

Netherlands, Belgium, Czech Republic, Sweden, Poland, United Kingdom
Sangart

Completed

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Ischemia | Hypotension

Netherlands, Belgium, Sweden, Czech Republic, Poland
Anders Perner
Rigshospitalet, Denmark; University of Copenhagen; B. Braun Melsungen AG; Copenhagen...

Completed

Scandinavian Starch for Severe Sepsis/Septic Shock Trial (6S)

Septic Shock | Severe Sepsis

Denmark, Norway, Finland, Iceland
University of Zurich

Unknown

Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury

Burns

Switzerland
The George Institute
University of Sydney; Fresenius Kabi; Australian and New Zealand Intensive Care...

Completed

Crystalloid Versus Hydroxyethyl Starch Trials (CHEST)

Intensive Care

Australia
Yonsei University

Completed

Respirophasic Carotid Artery Peak Velocity Variation as a Predictor of Fluid Responsiveness in Patients With Coronary Disease

Coronary Artery Occlusive Disease

Korea, Republic of
Max Dieterich
University of Rostock

Completed

Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty

Surgical Side Infections After Breast Reduction

Germany
St. Boniface Hospital
University of Manitoba

Unknown

This Study Will Compare the Effect of Starch Containing to Non-Starch Containing Intravenous Fluid on Blood Loss During Coronary Artery Bypass Graft Surgery

Bloodloss
Chung-Ang University Hosptial, Chung-Ang University...

Unknown

Study of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness

Thyroidectomy | Fluid Responsiveness

Korea, Republic of
Yonsei University

Completed

The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery

Coronary Artery Occlusive Disease

Korea, Republic of
Fresenius Kabi

Completed

Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section (CAESAR)

Hypotension

France
The Cleveland Clinic
Fresenius Kabi

Completed

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients (SHARP)

Postoperative Kidney Injury

United States
Seoul National University Hospital

Completed

The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery

Acute Kidney Injury

Korea, Republic of
Medical University of Vienna
Fresenius Kabi

Completed

Crystalloids Versus Colloids During Surgery (CC)

Postoperative Complications | Fluid Overload

Austria
B. Braun Melsungen AG

Completed

Plasma Volume Replacement (PVR) Therapy With Colloid and Crystalloid Solutions

Plasma Volume Replacement | Surgery of the Pancreatic Head

Germany
National Institute of Medical Sciences and Nutrition...

Unknown

Behaviour of Intravenous Solutions in Obese Patients Under General Anesthesia

Obesity | Obesity, Morbid

Mexico
Fresenius Kabi
B. Braun Melsungen AG; European Society of Anaesthesiology and Intensive Care

Completed

Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery (PHOENICS)

Hypovolaemia Due to Acute Blood Loss

Spain, France, Netherlands, Germany, Poland, Belgium, Czechia, Croatia, Austria, Romania
B. Braun Melsungen AG

Terminated

Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)

Renal Insufficiency

Germany
Samsung Medical Center

Completed

Stroke Volume Variation and Pulse Pressure Variation as Predictors of Fluid Responsiveness During Kidney Transplantation

Kidney Transplantation

Korea, Republic of
Fresenius Kabi Japan

Completed

Trial of 6% HES130/0.4

Hemorrhage | Hypovolemia

Japan
Fresenius Kabi

Terminated

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

Intraoperative Complications

China
Medical University of Vienna

Completed

Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery

Coronary Artery Disease | Valvular Heart Disease

Austria
Fresenius Kabi Japan

Completed

Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery

Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage

Japan
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

COPD

Belgium
Duke University

Terminated

KOREAN Enhanced RecOvery Strategy for Colorectal Surgery (KEROS)

Colorectal Surgery | Goal-oriented Fluid Therapy

Korea, Republic of
Asan Medical Center

Completed

Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy

Pancreaticoduodenectomy

Korea, Republic of
University Hospital Muenster
Fresenius Kabi

Terminated

Perioperative Colloid vs Crystalloid in Patients Undergoing Colorectal Surgery (KoKris)

Surgery, Colorectal

Germany
Celularity Incorporated

Completed

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Diabetic Foot | Peripheral Arterial Disease

United States
London Health Sciences Centre

Terminated

Starch or Saline After Cardiac Surgery (SSACS)

Coronary Artery Bypass Surgery

Canada
University of Debrecen

Completed

The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies

Subarachnoid Hemorrhage

Hungary
University Hospital, Clermont-Ferrand

Completed

Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study) (HAEMO)

Postoperative Mortality | Postoperative Morbidity | Hemostasis Change

France
Paraskevi Matsota

Completed

A Comparative Study of Volume Replacement With HES 130/0.4 Versus Ringer's Lactate (RL) Regarding Their Effects on Inflammatory Biomarkers (Cytokines and Matrix Metalloproteinases) Responses to Major Abdominal Surgery.

Postoperative Inflammation

Greece
BioMarin Pharmaceutical

Completed

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

Taiwan, United States, Italy, United Kingdom
BioMarin Pharmaceutical

Completed

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IV A

United States, Canada, France, Taiwan, Argentina, Colombia, Spain, Turkey, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, United Kingdom, Germany, Norway, Portugal, Italy, Qatar
Ibn Sina Hospital
Banon IVF Center Assiut, Egypt; Egyptian IVF Center

Completed

Triple-arm pH Comparison (Tri-pH)

In Vitro Fertilisation Outcome

Egypt
Cairo University

Completed

Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients

Anesthesia Morbidity

Egypt
Yonsei University

Completed

Comparison of 6% Hydroxyethyl Starch 130/0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass

Mitral Valvular Heart Disease
BioMarin Pharmaceutical

Terminated

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United Kingdom, United States, Germany
Seoul National University Hospital

Completed

Pulse Pressure Variation (PPV) to Predict Fluid Responsiveness During Cardiac Displacement in Patients Undergoing Off-pump Coronary Artery Bypass Surgery (OPCAB)

Ischemic Heart Disease

Korea, Republic of
Fresenius Kabi

Completed

Voluven® in Paediatric Patients

Cardiac Surgery | Cardiopulmonary Bypass

Austria, Belgium

Search clinical trials for: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations